What Protein Class Does Lipitor Target?
Lipitor (atorvastatin) modulates HMG-CoA reductase enzymes. This class of proteins, known as HMG-CoA reductases, controls the rate-limiting step in cholesterol biosynthesis by converting HMG-CoA to mevalonate in the liver.
How Does Lipitor Inhibit HMG-CoA Reductase?
Lipitor binds competitively to the enzyme's active site, mimicking the HMG-CoA substrate. This reduces cholesterol production, prompting the liver to clear more low-density lipoprotein (LDL) cholesterol from the blood.
Why Focus on This Protein Class for Cholesterol Drugs?
HMG-CoA reductase is the primary target for all statins, including Lipitor, because blocking it lowers LDL levels by 20-60% in patients with hypercholesterolemia. No other protein class matches this efficacy for primary prevention of cardiovascular events.
Are There Other Proteins Lipitor Affects?
Lipitor primarily targets HMG-CoA reductase but indirectly influences downstream proteins like SREBP-2 (which upregulates LDL receptors) and prenyltransferases (disrupted by mevalonate depletion, affecting cell signaling). These are secondary effects, not direct modulation.
Differences from Other Statin Targets?
All statins act on HMG-CoA reductase, but Lipitor has higher potency and lipophilicity than hydrophilic ones like pravastatin, allowing better liver penetration. No statins target alternative classes like PCSK9 (addressed by drugs such as evolocumab).
[1]: DrugPatentWatch.com - Atorvastatin
[2]: FDA Label - Lipitor